0
Clinical Investigations: PLEURAL DISEASE |

Pleural Fluid pH as a Predictor of Survival for Patients With Malignant Pleural Effusions*

John E. Heffner, MD, FCCP; Paul J. Nietert, PhD; Celia Barbieri, MS
Author and Funding Information

*From the Division of Pulmonary and Critical Care Medicine (Dr. Heffner) and Center for Health Care Research (Dr. Nietert), Medical University of South Carolina, Charleston, SC, and University of Arizona Health Sciences Center (Ms. Barbieri), Phoenix, AZ.

Correspondence to: John E. Heffner, MD, FCCP, Department of Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 812, PO Box 250623, Charleston, SC 29425; e-mail: heffnerj@musc.edu



Chest. 2000;117(1):79-86. doi:10.1378/chest.117.1.79
Text Size: A A A
Published online

Study objectives: To assess the accuracy of pleural fluid (PF) pH in predicting duration of survival of patients with malignant pleural effusions.

Design: Analysis of patient-level data from nine sources retrieved from a MEDLINE search and correspondence with primary investigators.

Study selection: Published and unpublished studies that report PF pH values and duration of survival of patients with malignant pleural effusions.

Data collection and analysis: Primary investigators supplied patient-level data (n = 417), which was examined by receiver operating characteristic (ROC) analysis, logistic regression, and survival time modeling to determine the utility of PF pH for predicting survival compared with other clinical factors. The primary investigations were graded for study design.

Measurements and results: Median survival (n = 417) was 4.0 months: PF pH (p < 0.0039) was an independent predictor of survival duration. A PF pH test threshold ≤ 7.28 had the highest accuracy for identifying poor 1-, 2-, and 3-month survivals. The predictive accuracies of PF pH (area under the ROC curve range, 0.571 to 0.662) and a PF pH–high-risk tumor (lung, soft tissues, renal, ovary, gastrointestinal, prostate, and oropharynx) model (odds ratio range, 2.91 to 6.67), however, were modest for predicting 1-, 2-, and 3-month survival. Only 54.4% and 62.7% of patients identified by PF pH ≤ 7.28 or the PF pH–high-risk tumor model to die within 3 months were correctly classified. Weaknesses of the primary data were identified.

Conclusions: PF pH has insufficient predictive accuracy for selecting patients for pleurodesis on the basis of estimated survival.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543